The event will bring together innovators, investors and industry leaders to explore the latest advancements and trends shaping the future of healthcare in Saudi Arabia
New York, NY – June 16, 2025 – J.P. Morgan Asset Management’s Life Sciences Private Capital and King Abdullah International Medical Research Center (KAIMRC) are pleased to announce the 10 finalists of the second annual Life Sciences Innovation Summit. The Summit will take place on October 1-2, 2025 in Riyadh, Saudi Arabia. The event will bring together innovators, investors and industry leaders to explore the latest advancements and trends shaping the future of healthcare in Saudi Arabia.
“The infrastructure in Saudi Arabia is ripe to become a leading center for therapeutic innovation,”
– said Stephen Squinto, Ph.D., Chief Investment Officer of J.P. Morgan Life Sciences Private Capital.
“We are delighted to partner with local leadership in Riyadh to host our second annual Life Sciences Innovation Summit.”
Finalists selected to compete in the Summit include:
- Cellestial Health
- EpiBone
- Fimmcyte Therapeutics
- Genethon NewCo
- NanoPalm
- Neurenati Therapeutics
- Rinri Therapeutics
- Script Biosciences
- Synthis Therapeutics
- Ten30 Biosciences
”We are thrilled to partner with J.P. Morgan to host distinguished scientists, business leaders, regulatory officials, and investors at KAIMRC, showcasing our capabilities in biotechnology. This collaboration aligns with Saudi Vision 2030 and our commitment to advancing a robust biotechnology strategy that drives scientific progress and enhances health outcomes,”
– stated His Excellency Dr. Bandar Al Knawy, CEO of the Ministry of National Guard Health Affairs and President of KSAU-HS.
About J.P. Morgan Life Sciences Private Capital
J.P. Morgan Life Sciences Private Capital (“LSPC”), is the life sciences platform of J.P. Morgan Private Capital, the investment arm for private companies across the capital structure with a focus on venture and growth investing within J.P. Morgan Asset Management. LSPC partners with leading early-stage biotherapeutics and late-stage healthcare companies. The early stage biotechnology practice is focused on company creation, Seed and Series A investments across all therapeutic areas in biotechnology. The late-stage healthcare practice is focused on Series B through pre-IPO investments within biotechnology, medical devices, tools, diagnostics, healthcare technology and pharmaceutical services.
About J.P. Morgan Asset Management
J.P. Morgan Asset Management, with assets under management of $3.7 trillion (as of 3/31/2025), is a global leader in investment management. J.P. Morgan Asset Management's clients include institutions, retail investors and high net worth individuals in every major market throughout the world. J.P. Morgan Asset Management offers global investment management in equities, fixed income, real estate, hedge funds, private equity and liquidity. For more information, visit: www.jpmorgan.com/am
JPMorgan Chase & Co. (NYSE: JPM) is a leading financial services firm based in the United States of America ("U.S."), with operations worldwide. JPMorganChase had $4.4 trillion in assets and $351 billion in stockholders' equity (as of 3/31/2025). The Firm is a leader in investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing and asset management. Under the J.P. Morgan and Chase brands, the Firm serves millions of customers in the U.S., and many of the world's most prominent corporate, institutional and government clients globally. Information about JPMorgan Chase & Co. is available at : www.jpmorganchase.com.
About King Abdullah International Medical Research Center
The King Abdullah International Medical Research Center (KAIMRC) stands as a prominent leader in biomedical and clinical research. Established in 2006, it operates under the auspices of the King Saud bin Abdulaziz University for Health Sciences (KSAU-HS) and the Ministry of National Guard Health Affairs (MNGHA). Located in Riyadh, with additional campuses in Jeddah and Al-Ahsa, KAIMRC is dedicated to advancing healthcare through innovative scientific discoveries and research.
KAIMRC is recognized for its pioneering work in Biobanking. The center's Saudi Biobank is ISO accredited that is equipped with more than 60,000 samples, playing a vital role in the collection, storage, and management of biological samples from a diverse population. This biobank facilitates critical research into genetics, disease mechanisms, and personalized therapies given its ability to link biological samples to clinical data.
Additionally, the Cellular and Molecular Biobank (CBB) specializes in the collection and preservation of human cells and tissues. Operating under Good Manufacturing Practice (GMP) standards for CAR-T cell therapy, the CBB ensures the highest quality and ethical compliance in its operations, significantly contributing to advancements in cell therapy.
With over 100 global partnerships, KAIMRC is at the forefront of innovation in clinical trials, cancer and rare diseases diagnostics, and therapeutic developments. In 2023, it earned accreditation from the Association for the Accreditation of Human Research Protection Programs (AAHRPP), further solidifying its reputation for excellence in research.
SOURCE : J.P.Morgan Asset Management
